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lt is indeed an honor to be the Beerman Lecturer 
this year. 1 have never ha d the pleasure of knowing 
Dr. Beerman personally but have long been aware 
of his going reputation as a dermalopathologist 
and his marked contributions to the growth and 
intellectual nourishment of your Society. When I 
was firt-l invited to speak here I wa~ mvited to 
speak on cellula r im munology a nd recent work in 
our laboratory in this area. However, several mem -
bers of your Board of Directors suggested that in 
view ot the fiscal '"c runch" affecting me mbers o f 
this Society as well as biomedical research in gen-
eral. a presentatron dealing nirh some of the ro!>t 
benefits ol biomedical research might be worth-
while. They also suggested that this presenrat10n 
be followed by sugges tions of how we can best dis-
seminate information gathered in th1s area to our 
colleagues. to the citizenry, to Congress, and the 
Admimstrat10n. 
Data on the cost benefits from basic and applied 
biomedical re~;earch indicate tha t benefits have 
exceeded the cost by 20-fo!d [1, 21. Hence, cut -
backs in funds for biomedical rehea rch represent 
fiscal irresponsibilit~ (to say nothing o f throwing 
away chances to save lives, end m isery, and so 
forth ). Since the latte r apparently n o longer seems 
important in the minds of the Adminis tration. this 
presenta tion will be confined to tangible be nefits 
(like dollars). 
We are all aware that fundin~ ol biomedical 
research in the past li\"e years by both the :'\IH 
and, to a lesser extent. by the National Science 
Foundat ion, and reported allocations by the Ad-
ministration for the next fiscal year, have remained 
at more or less a constant level. Al t hough increased 
funds have been given to cancer and heart diseat-c. 
cut~; in a ll other a reas j:Ja I have caused '"consterna-
tion a nd apprehension ... throughou t the aca-
demic community'" lab) (See Appendix AJ. In 
effect. inilation has eroded bio medical research 
fundR on the order of :l0-3:J percent since 1969. 
Many promising new prol{l"ams with line potential 
have not been funded ; many good programs have 
been dis mantled; and training program!> have been 
eliminated in spill' of effort s hy our:;elves and 
others. It appears that the training prog"rams may 
be reinst ituted in small part fo r three years but on 
a basis which may rwt he workable for the vast ma-
jority of medical schools and other research in~t i-
tutions (funds only fnr lrainees; nunc for supplies. 
technical help. salaries for instructors. etc .). As 
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you are probably awa re. bright vuung people tnter-
ested in careers in biomedical research are becom-
tng ever more reluctant to enter the lield as they 
see the1r predecessor>-. ~raduated three or four 
yea r" earlwr w1th earntn{.(~ well belo'' tho~e ol 
people" ith comparable trainm~ in pri,atc practice 
or industry. u nable to obtam research ~rant s. Th1s 
will undoubtedlv cause a c risis five or t en vears 
hence. 11 may therefi1re come as some surpri~e to 
you to find that eminent ~cienC'e writert-. such as 
.John Lear of The Saturday He,,ie\\ . within the 
past yea r or two ha\'e called for a reduction in ""the 
ever proliferating biomedical research grant:. .. and 
""a return o l researchers in to proctice hO health-care 
delivery manpower would be increa~ed ... A., ."ou 
know, the pe rcentage of physicians in full -time 
research is minute. 
Furthermore, s tatements about the "useless ex-
penditures·· lor ··ivory tower re~ea rch'" ha\e been 
made by leaders of the American Medical Associa-
tion an-d the relevance of such research is often 
questioned by today's medical studen Ls. fn a year 
of i ncreasin~ demands on the Federal budget it 
seems that the justification of biomedical research 
in terms oft he improvement of 1 he quality of life is 
no longer :;uflicienl to convince the Admini;;tra-
tion , Congress, the ~eneral public. and, indeed, our 
own colleagues in pari tha t these expenditures 
deser\"e high priority. For example. Mr. Welll-
berger. Secretar) of HE\\', has recently likened 
cutbacks in expenditures for ~ome med1eal pro-
grams to the dismantling of certain defen~e bases 
which were no longer needed. I belie,•e it io. impos-
sible to say that medical research is ··no longer 
needed"" or W identil\· those 11rea. that 11re ··no 
longer needed ." :\o ~ne knowt- what accident81 
finding in a laboratory of an inquist ive invesug;IIM 
will e,•entualh save $1 2 billion a year. Unlnrtu-
nately. scientists have neglected to document the 
vast economic ~avings resulting from pa:,;t expend-
itures. We are a ll aware that th is count r, "s bio-
med ical research establ ishment is second to nune. 
In c<mtrast to European :.choob, for example. our 
basit and clinical science departments a re closely 
connect ed, and training l{l"an ts in the past have pro-
vided deliberat e encouragement fo r people ahlr to 
function at both ba:;ic and clinical le,·eb who can 
translate ba~ic scientific obsen·ations into clinical 
application. This ha!l worked in a fe\\ in:.titute!> by 
method~ ol her than training grants but only when 
outstanding rel>ea rch scientists work in clo~e prc1x-
imity to people with access to hospit al beds. A 
recent illustrative development occurred at such 
an institution. the Rockefeller Institute (now the 
Rockefeller l 'niversityl where people workinl! on 
protein :.tructure-cul mimll ing in t he :-.;obel Prize 
(.tj-used u rea to denatu re protein;. a few years 
322 THE ,JQl R!\AL OF 1'>:\·F:~TIGATI\.F. 0EI{\1ATOLOG\ 
ago. A lew vears Hgo tt looked as though urea might 
be useful in the treat rnent of sickle cell anemta. 
but sud1 therap~· required huge dose:-. and controls 
were never used. The Stein and Moore groups at 
Rockefeller found that cvanate was a eontaminant 
of the urea l-11: sub~eq.uentl~. a grnup ot bright 
younf! mve:.tigatol'!. concluded that perhaps it 
was the cyanate in the urea that wa~ beneficial {!1. 
6]. 1L appears th~ll cyanate does not h11ve the side 
effects of urea and this observation will save the 
country million~; of dollars each year since 10 per-
cent of our :s-egro ctllzenry have the sickle celllrlttt 
and about 1 perc·ent stckle cell disease. I have not 
cost accounted these saving-s vet. hut they will 
probably he immen!:>e. 
In any event, the progressh·e dismantling of 1 he 
training grant mac·hinery and the pos!iihility that 
research grant>. will be evaluated not by peer 
re\·iew but by some other mechllntsm represent 
grave threat:,. This progressi,·e dismantling of both 
research and training grants appears inevitable, 
and indeed u·ill be in e-.. itahle unless the public and 
their elected representative:. can be shown that 
this policy is liscalh mesponsihle trom 1 he pomt of 
view of the O\•erall social good. 
In altempb to obtain data bearing on cost 
henefit analyl:'is of basic research. endeavors which 
are e\'entually translo.ted into eradication and 
prevention of disease, or new therapeutic and 
diagnostic methods which sa\e both time and 
mone~ for patients and phy'::>itinn~. I surveyed 
certain diseases and research area:; where fist' Ill 
data were available. To compare henefils wilh 
costs an economic measure of henefils was needed; 
for this I applied the methodolo~ for estimating 
the economic value of human life which was dealt 
with h\ Rire. a nuted economist. about ten vears 
ago \7 .' B ]. The method11logy for cost benefit a·naly-
sis in the health field was reviewed ahout fi,·e years 
ago by Klarman. a di~tinguished biometrician. and 
one of I he criteria used was earnings as an eco-
nomic worth of the mdividual [91. The present 
value of an indi\ idual's expected ltfe!tme earnmgs 
is the indirect economic cost to society of his death. 
and the cost which would be saved from di:;eases 
which require lifelong in~t itutionalizat inn-the in-
stitutionalization cost~-.. the lo>-s of earnmg"' t<lsh, 
etc. Future earnmgs were com·ertcd 10 pre:-ent 
,•al ue hy the use of an arbitrar~ discount. such as fi 
percent, reflecting the fact that the dollar a\'ailahle 
for u!.e now is worth more than the dollar which 
will be available some lime in the future. The 
dollar figures presented reflect the cost of mediral 
services. drugs. hospitalization. in,.,tittttionaltza-
tion (when this is significam ('Ost for C'hrontc 
disease) . and. in addition. the loss of earned 
income during hospitalization . Let's ;;tart with one 
major disease eradicated within our lifetime which 
has resulted in tremendous sa\'ings. namely polio. 
Polwmye/iti.\. The haste findmg which enabled 
product ion of the polio vaccine ''as ob,.ervecl hy. 
Enders twho reccivrd the Nobel PrizPl that viruses 
could he grown in monkey tissue culture"' [lO]. 
Enders was not intere:;ted tn polio but rather in 
developing a means of propagating \'iruses so he 
could work on the po~si ble role of viruses in cancer. 
:\onethele,.,s his ohser\'ation. followed by tho:,e of 
others. led to the tntrorluctum of the Salk and 
Sabin polto vaccines. Other work by immunolo-
gists showed that an orally admini1.tered vaccine 
rather than one administered intramuscularly or 
subcutaneou!<ly was preferable since it led to ~ore 
protection even though !'.erum antibody le\'els were 
the :;arne. The senetory tmmunoglobulm antibody 
was much higher followtng oral admintslration 
(reviewed m poj). This basic research was not 
directed toward vaccines per ;,e, but rather toward 
answering some fundamental questions about the 
immunology of the ga:,twintestinal tract. 
The Table details one means of analvzing ~;uch 
data The base line is the six-year period hefllre the 
polio vaccine was introduced and the experimental 
period is the six-\ ear period alter the vaccine was 
introduced. Ra;.ed on the int'idence of polio in the 
years ju<;t before the polio vaccine. 1:1-t.OOO cases of 
polio were prevented between 19:->5 and 1961. Of 
those affected during this period-again using as a 
control the period before the Salk \·accine-12.f>OO 
individuals would ha,·e died and 14,:~00 would have 
experienced complete disability. Of the remainder. 
36,-tOO would have been disabled. !liUOO moder-
atelv disabled, and 3:3.700 would ha,·e suffered onlv 
l'>light dtsahilit~. The estimated medical care costs 
were S327 million and the In;;~ of earned income 
over lifetime was estimated at $6A billion . The 
bas ic vaccine research and field trials cost $41 
million. whereas $6 billion, or more than Sl billion 
a )ear. were saved. The e;;timated cost of avoid-
ance (the cost of the ,·acrtnc. the co::;t of adminis-
tration. the ph,·stcians ancl nur~es. etc.) rotaled 
$611 million 181. 
The lntal cust wru. on!\' ahout I 0 percent of the 
amount saved-that'~ $6 billion sa,ed over a 
six-year period. or Sl billion a year. I would like to 
point out to you that the total annum extramural 
budget <tf the ~atinnallnstttute of Allerg-.. and ln-
l'ectious Disem,es is abou1 Sill million a year for 
extramural funds. so there is a ~aving of$1 billion 
a vear {8\-much more than the total expenditures 
of the Aller~ and lnfectiou,., Oi~ea"e fnstnllle for 
immunology sinc·e the ln~titute's inreptton. Al -
though $1 billion a year was "aved from 19!l!) to 
1961. in view of the incrca~e in population. infla-
tion. and the large increBse in hospitalizatton and 
institutionalization costs, the current E'~t imate 
i:s that we are saving $:! billion a year from 
eradication uf poliomyelitis. Thi!' doe, not1nclude 
intangible ec·onomic benefits such as lhe sale of 
swimming pools. !;econcl homes at lakrshorc re-
sorts. the ;;wimsuits. etc. whirh l've been unable to 
calculate. 
Tubrrculost.~. The sa\ ings from other dt~eases 
were cnmputecl the ->arne wa~ For example. let's 
take tuherculo,.,,,.,_ The serendipitous finding::; of 
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Nobel Laureate S. Waksmnn of Rut~:ers, a soil 
microbiologist of diverse interesh. led to the ap-
plication of streptomycin to the treatment of 
tube rculosis. This was found on I)' by accident. and 
perhap~ is an argument for ~upportmg people of 
known productivity by a ~:rantin~ mechanism 
which provides considerable 11cxihility. (The cur-
rent emphasis on contracts rather than grants 
means that people will be unable to explore seren-
dipitous lindin~. no matter how enthused they 
will be. This busines!-.man 's appruarh to medical 
research will undoubtedly cost the countr) en or 
mously in terms of what we get for our ref;earch 
dollar.! 
Retunung to tuberculosis. r he average cost for 
hos pitalization was $15 per day m 195.J: in 1969. 
the last period for which I was able to get nation 
wide figures, Jt was ;::;~8 per d»y. For hospitalized 
patients in the municipal hospitab of :-\ew York 
two years ago. it was $91 per day. My fi!(ures are 
based on the $:18 per day. During the period 
1954 1969. the last period for which I have data. 
savings in hospitalization costs, computed again 
on the average duration of stay. etc .. wa!> $4.19 
bil lion. If one subtracts from this the costs of 
outpatient care of those pat ienls who were not 
hospitalized, namely SOA2 billion, a saving~ of 
s:l.77 billion remains in hospitalization cost!-. alone 
[12). It would undoubtedly be ver) useful to u;..c 
the same analysis for dermatologi(' disease::.. In any 
e\'ent, a consen·ati \·e estimme of the savings in 
income due to chemotherapy oltuhereulosis i!> $1.2 
billion, and therefore the total estimated economic 
benefits were S5 billion durin~ tht> period cited. 
During this game period of time the Congress of the 
United States allocated les~ than one-sixth of this 
$5 billton amount to the :-\ational Institute ot 
AllerJzy and Infectious Disease, for -.upport of 
research and training in all areas of inlectiou;.. and 
immunologic dt!iease;,. Incidentally. a recent study 
from the Albert Einstem M edicul School indicated 
that the average dail;.. cost for home care for TH 
w~ $ 11.55 per day per patient on these outpatient 
medication!; in contrast to the .~~17 per da:. citt•d 
earlier. The Albert Einstein report ulso stated that 
:126,800,000 
6,:!89, 70{1,(1()() $6.7 I 11,500.000 
t29.800,000 
4AA,600.1l<X> 
_!.:\~1~>.000 
$6tt.700.000 
4t.:IOO,OOO $6il:l,OOO,OOO 
patients treated at home tended to do much better 
than those hospitalized 11 ). 
Measles. Another area which has demonstrated 
considerable economic sa\'ing:-. is measle~. again 
through a vaccine as in polio. The incidence of 
encepha litis. the incidence of death. and the inci-
dence of mental retardation which requires at leas t 
long-term and perha ps total institutionalization 
was computed using the same methods as used tn 
polio. In 1961 it cost $:\,000 per patient per year to 
institutionaltze pattents; now the cost is approxt-
matel~ triple. In an~ e'en!. using the 196! figure 
and the four years from 196:l to 1967 (the \'aceine 
was introduced about 1961 ), the net sa\'ings to our 
society after subt racting immunization costs were 
around $ 100 million a year-again. more than the 
total budget of the :-Jntional Institute of Allerj!y 
and Infectious Disea~e;... The basic re~earch whit h 
led tn the measles ,·an·ine a,·erted [2. l!lj 9.i 
milium acute ca;,e~ ol mea!>les during the fi,e .yeur 
period 196:~ 196 and about :l,OOO ca~es of mental 
retardation. with resultant c~timated :,8\Ing~ uf 
1)!),000 hospital beds, 291.000 year5 of normal life. 
more than 1.6 million work day~. 32 million school 
days, and, again, about $Hl0 million per year. 
lnridemally. about 9() percent ot the savings in 
each of these categories wa!; realized in the last 
three year., for which data are available, so I think 
our ligures are low on a per year category. C'urrent 
savings are estimated as at least $180 million per 
year. 
Rh di~:oea.,r. Another area in which ha;.ic im-
munologic researeh led tn eradication of a disease 
was hemolvtic disease of the newborn caused hv 
administra-tion of antt -Hh anlihodies to Rh-neg~­
ti\f~ mothers. This came ahout be,·ause people in 
thi~ field. ob~tetrieians and other». "aw that ani-
mal expenmenb designed to ... tud~ feedback um-
trol of antibody ~ynthe:-.ts showed that small 
amounts of antibody pre,entcd ;,ubsequent ami-
body formation em exposurP to antigen [I 1. If! j. 
Again, thi!> was first donP on nnimals [If!. l6l and 
then it wa!:i taken to Hh-negathe women [II, IK]. 
As vou all know. giviug ~mall doses of 11nti-Hh to 
Rh negative women has resulted in almost com-
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plete eradication of thi:- di!.ease (so much so that 
companie:- that make anu-Hh commercially are 
havin~ trouble ~etting donors). In any event, this 
has eliminated about 7.500 case~ of anti-Rh disease 
annually; about 6 percent of these had cerebral 
dysfunction; this 6 percent required about $11 
million tor special educational and rehabilitation 
facililie~ [1, 2]. 
Advances in Rh immuniL.atlon a\;;o abolished 
almost completely a cerebral p;.tl!-'v in premature!-' 
weighing less than 2 .. )()() g-m. 01)\'iously, children 
so affeeted from hemolytic disease of the newborn 
would have a great decrease in enmomic pmdu('-
tivity [191: co::.t ligures are not fiVailahle. unfortun -
ately. Attempts to obtain some of these l'if{Ures 
from the NIH have been almost impossible as have 
been attempts to get priority scmes lor grants 
awarded to do research in the ha.-,ic research areas 
which led to the clinical progress. These pnorit) 
scores were released only if invest i~ators would 
permit su('h release, and in some of these areas 
and in othel'l- discussed below. the priority scores 
funded at that t ime-e\'en so met h1ng that has 
saved us $100 million a year. derived from investi-
gation supported by $50.0(Xl yearly for three years 
-were such that at pret-ent the J(rant:-. would not 
he funded . At present mo~t basic re..,earch 1s not 
considered "relevant'· w human di;,ease and there-
fore gets a lower priori!). The Hh story is also of 
interest not only hecaust> 1t saves money but also 
bel·ause it has made 11 pos:-.ihle to reassure hun· 
dredo;, ol thousands of Rh-negative women by tell-
ing them their chance~ of having diseased infants 
due to maternal immunization to Hh antigen:-. a re 
ne!{l i!{ihl e I ~0 1-
Viral hrpatitt,\. Let',.. turn to an area in which 
work was carried out on human;. since its inception 
but in '' h1ch the research wa~ totally unrelated to 
what re:-.ulted. namely. a diagnostic test lor com-
mon \ira! hepatiti~ of the serum hepatiti~ variety. 
ll is estimated that at least :10.000 people are 
hospitali1.ed every year with trnnsfusion-induced 
(serum) hepatitis. Several year-, ago the estimated 
total cost of patient care was about S60 million 
yearly: thi ... does not include the patients that 
developed chronil· active he pat 1t 1:-. and were hu,..pi -
talized for yeaf'i he[ore death. Lo,.;t earnin~>- in the 
group that recovered "as s:m million or more at a 
minimum. and 5 10 percent suffered permanent 
liver damage and died alter prolonf.{ed illness and 
ho~:>pitali?.at inn. This hvspitaliJ.ation cost was even 
greater than the loss of income and ho~pitaliunion 
of those that rewvered without thi ... chronic hepati -
tis Ill-
About 12 year, ago. Dr. B. Blumberg. a popula-
tion genetiCist interested 111 genetic variation of 
human bemg;;. was mn•,..t igat 1ng hereditary \'aria-
lion~ in blood «erum uf protein" u,mg 1mmtmolngir 
technique!>. Quite by accident. durin!{ a world ~wide 
survey, he and his collcn).(ue~ li>und one particular 
antigen occurring in great frequenc~· in the blood of 
Australian aborigines [211. Later. he found that 
high levels of anubodie,.. to thi~ same antigen 
occurred in American patients who had received 
multiple blood transfusions. He thought this was 
genetic and similar to the blood group antigen;;,. 
By 1968. further resear<'h by many scientists 
throughout the world led to the conclusion that 
'"Au~tralian antigen" was not a hereditary genetic 
variance but rat her wa~ related to the virus aslloci-
ated with "transfusion hepatitis" [22. 2:ll. The 
virus was present in many asymptomatic indi .. ·idu-
ab, and thus was present in many blood donors. 
Since more than 10 million unit~ of donated blood 
are used in the United States each year tand the 
amount eUmhs vearlvl. the need for a reliable test 
to detect the virut- before a donor gives blood is 
ob\'iously great; such tests ha .. e been devised in 
the last couple of years. There is nO\\ a radioim-
munoa:-.say which detects the viru~:>(24, 25], and the 
Federal Go,·ernment ha!> passed a bill which wiLL 
require ··Australian antigen" tests to be done on all 
donor bloods. Sin<'e the test cost!i onlv :l5t and 
blood costs at least S:35 a unit. it il> expected that 90 
percent of transfusion hepatitil:'. will be eradicated 
at a savings of at lea!it SlOO million yearly. 
Rf'nal tran~oplantatum. There are several things 
that ha' e led to tremendous cost sa\ ing~ in renal 
transplantati<>n: one i::; the de..-e\opment or HLA 
antigen typing, the other the development of 
immunosuppressi,·e drug::;. Roth were desig-ned 
originfllly for purpose;. other than renal transplan-
tation. In terms or HLA typing, some year,., ago two 
immunogenelicists, Dausset in France and Payne 
at Stanford. who were working with hereditary 
variation ot red cell ant igcns, decided to look for 
hereditary \·ariation in white cell antigens [26, 271. 
At that time they had no idea this would be 
relevant to t ran;;plantat ion. Thev did. mdeed. 
di:,.co\·er that there were hcreditan: variat1on~-at 
least 2fi different hereditary white cell antigens 
(so-called HLA antigens) in man. present in white 
cells, ski n, kidnev. and also in hear!, etc:. Tissues 
grafted from one individual to another are rejected 
unle~s the H LA antigens of the two 111dividuab are 
identical or. depending on the tissue. unless un -
munosuppressives are u;;ed. Good matche~ at the 
HLA locus require only one-seventh a::; much 
ho~pitalizat ion a~ poor matche~. even il the poor 
match graft sun 'l'e" I2HI. Hospitalization cost:-. fur 
renal transplants are about $10,000 per patien! per 
year. There are about 10,000 cases ol chronic renal 
disease in this country and it is estimated that all 
of the;.e could be t ran-..planted about three years 
from nnw-hence an estimated !Saving~ of S100 
m1llinn in good match n. poor match [ 11. 
lmmunosuppres:-1\'e dru!{s were 11.-,..t used in 
animal experiment~ b~ Dr. Robert Sch,,artz in 
Bo!iton !191. These 1111111Uno~uppre,-..i,·es were oril!-
inally u~ed as antinenpla;.tic agent~. Dr. Sch\\artz 
was intcre~ted in whether the effect, il any. of 
antineoplasti(' ag-enb on the immune re~ponse; 
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they indeed showed a dramatic effect. and all these 
agents have subsequently been dramatically suc-
cessful in the transplantation field. 
Hemophilia . Cost benefit data can also be ascer-
tained in other fields, e.g., cryoprecipitate treat-
men I. of hemophilia. etc. As a prophyl11ct ic meas-
ure it represents an estimated savings of $100 
million a year. The original work leading to this 
was a "fallout" from a very small grant designed to 
isolate and characterize antihemophiliac factor. In 
any e\'ent, administration of cryoprecipitates to a 
hemophiliac once a week prevents the joint bleed-
ing that occurs in patients not treated in this way 
[30). 
Retrolental fibroplasia and blindness. One very 
fascinating area where I've been able to get almost 
complete data is blindness due to retrolemal 
fibroplas ia. Around 1949 a very serious epidemic of 
retrolental fibroplasia and blindness occurred in 
this country. This was due to administration of 
pure oxygen to infants with respiratory distress 
syndrome-also termed the hyaline membrane 
disease. Between 19-19 and 1953 there were between 
3,000 and 4.000 cases of retrolental fibroplasia and 
blindness. During these yPars the Nl H allocated 
$750,000 for research in this area. Dr. Patz. an 
ophthalmologist at ,Johns Hopkin!>, received 
$37.000 for his research in animal models and in 
humans and discovered the relationship between 
increased oxygen and retrolental fibroplasia 1:11. 
:3::!]. Since we sti ll don't know the cause of the 
premature respiratory distress syndrome, it is 
conceivable that without Or. Patz's work we s till 
would not know the cause of retrolental fibroplasia 
and blindness. Even if someone else would have 
discovered it within four years (probably a conserv-
ative estimate), and s ince the loss of income is at 
least $4,000 a year in a blind person relative to a 
person with normal vision, the $750,000 turns out 
to be a saving of $100 for each dollar spent. 
assuming 50 years of income depreciation . About 8 
percent went to Dr. Patz 's resea rch; T'rn sure that 
other 92 percent wasn't a complete loss-but e\'en 
assuming it was, at least $100 was saved for each 
dollar spent. Had Lhe cause not yet been discov-
ered, this then would be approximately $25,000 for 
each dollar spent . 
Parkinson's disease. Examples of tremendous 
cost savings when an informed mind became 
interested in one or another problem abound. For 
example. Dr. Cotzias of New York. workin~ at 
Rockefeller and Brookhaven, was considered one of 
the CounLry·s experts in renal metabolism of man-
ganese and other trace meta ls. orne years ago a n 
episode of a Parkinson 's disease-like >.yndrome oc-
curred in manganc;,c workers in Chile. He recei,·ed 
a grant for $20.000 from the :\IH to _go to Chile and 
estimate the manganese levels in the brains ot 
the miners who died: he found that the manganese 
levels were not increased. Nonetheless. because 
of this he became interested in Parkinson's dis-
easet. He went back in the neurochemical litera-
ture and found that neurochemists had shown that 
the dopamines of the brain were depleted m 
Parkinson's disease patients. He developed some 
animal models and decided to treat these animals 
and then humans with L-dopa. He came across 
some experiments in the older literature where the 
same thing had been done without success. His 
inve:;tigations showed that dopa was a mixture of 
L-dopa an:l 0 -dopa, that 0 -dopa wa" toxic and 
would limit the amount of dopa that could be given, 
and further that 0 -dopa mterfered with the action 
of L-dopa. He started giving a larger dose of L-dopa 
for Parkinson's disease with marked success. Using 
the figures I've obtained for the incidence of Parkin-
son's disease. the average age of onset. the avera~e 
economic status (upper middle class). the average 
time before the patient'~ crippling require>- inst i· 
tutionalization, the institutionalization costs, etc.t 
as for polio. the average saving;; are $1.2 billion a 
year ll ]. This again shows the value of giving an 
obviously productive worker fund::. to explore 
wherever he thinks is going to be important. Had 
he not been working on mangane!>e. he wouldn't 
have gotten interested in Parkinson's disea!;e. As 
you probably know. he wa;; awarded the Lasker 
Award this yea r for his W(>rk in Parkinson's disease. 
Papanicolaou smear. The Papanicolaou smear is 
saving $1.1 billion annually due to early detection 
of carcinoma of the cervix. Papanicolaou wasn 't 
interested in carcinoma when he started thi:-. ; he 
was only interested in seeing whether the cytologic 
changes in the cervi x differ at different phases of 
the menstrual cycle, but by accident his informed 
mind was able to take advantage of that set of 
findings. He was able to find that this was a very 
valuable test for early detection of carcinoma of the 
cervix. Grade IV carcinomas of the cervix are 
inoperable and cost a fortune for radiation and 
su rgery. Grade f' s can be cured in 99 percent of 
patients§. 
AmniocPiltf'sis. Let 's look into the future. As you 
know. enzvmes and chromosome:> were formerly 
considered-the best examples of pure ··ivory tower:, 
research. There was nothing more "ivory tower·· 
(i.e .. with no practical application) than this. Now 
we know of a whole host of chromnsomal abnor-
malities and a whole hos t of enzyme abnormalities 
which can he detected by amniocentesis in the 
pregnant mother a t about six weeks ges tational 
age. Presently in most states, it a mother is having 
a child who is going to be hospii ali zed for life. 
abortion is permissible. With these technique;; now 
+ Cot7 ia» G: Pen-.onalcommumcatinn 
:j: Yahr :vi, Parkinson's Dbease Foundation. ~ .\' .. 
per..onal communical ion. 
§ Melamed M. Director. \) wltJg). :'1.1emonal Hn~J'll· 
tal, ~.Y .. personal wmmunicatinn. Ross \\'L ,Jr. Eco-
nomic~ nt C'an(·er ('om rot. Proc \\'orld Cnnlerence on 
Cancer of the l 1terul<, :'\ew Orlean~. March 2 fi. 1969 
(spon~ured hy Amerintn Canc£'r Society). 
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applied at the clinical level, it is estimated we will 
save at least $:1 billion yearly in institutionaliza-
tion costs alone [33] . This is a conservative esti-
mate. In 1968. in Ma!'sachusetts, all pregnant 
women over 35 who had a high risk of mongolism 
were studied by amniocente:;i!i. Detection of mon-
golism resulted in savtnl(l> pret'ent I) estimated at 
more than S2.;) million (:'-t] . Il one extrapolates thts 
lO the total United States population just for this 
one disease in htgh -risk mothers. there is an 
anticipated saving of Sl 00 million yea r I) [3:n 
There are at least :.!9 enzvmatic defects (and more 
are turnin g up each month) that can be diagnosed 
prenatally [35], and amniocentesis not only spares 
the mothers with previously affected infants the 
anxiety of having another malformed child. but 
saves mothers carry ing a normal fetus the mental 
trauma during the last three-quarters of pregnancy 
worrying whether the infant will be abnormal or 
not. and saves the in~:.titu tionalization cost for a 
lifetime of affected infants. (ln another context. 
there il> a bill currently hetore CongreS~> to prevent 
the NIH from funding any research to do with fetal 
tissues. but I would submit to you that this is one 
case where l thmk most Americans would feel that 
the cost sa\'lng, as well as the savings in mental 
anguish of the parents really warrant further 
research.) 
Owen McCrorv. a consultant 111 medical eco-
nomics. estimates that in t967 alone. the 2.7 
million wage earners alive and working, owing in 
part t<> new modalities of therapy, paid the Federal 
Government $1.7 billion in income and excise taxes 
on their earnings. The NIH appropriation for that 
year (liscal 1967) was $1.4 billion . McCrory con-
cludes from his analysi~ that the funds appropri -
ated in fiscal 1970 to the ~IH and the Mental 
Health Admini!>lration havl.' been repaid to the 
Federal Government ei~ht times over in income 
and excise taxes of wage earners whose lives have 
been sa,·ed due to medical re»earch successes. The 
decrea;.ed rate of mortaltt~ ts not attributable 
solely to developments through ' I H programs; 
however. these data refer simply to prevemion of 
death>., and take no account of the enormous cost 
of illness [:16}. 
Dipitali.\ serum level.\. Other example~ that will 
save us tremendous money in the future abound. 
For elCample, patients with heart failure enter the 
hospital with nausea and vomtting. The physician 
doesn't know whether the patten! is on too much 
digitalis or too little, and withholds treatment 
for three or more days. Hospitalization and loss of 
work results in tremendou:; t'Osts. Antibodies to 
digitalis were developed initiallv bv people who 
were interested in whether rabbits can develop an 
immunologic respon~:.e to verv ;,mall molecule~> 
[37]. The~ had no idea of applvin~ tt clinically at 
that time. but no\\ the technique can determine 
in a very shon time ·whether the pat1ent has too 
much digitalis in the circulallon or too little j:3R]. 
Further, it has been pos~ihle to rever:,e dtgitalis 
intoxication tn rabbits using the antibody coupled 
to a carrier and passing the serum over t\ as one 
would during renal dialysis . This is shortly I{Oing 
to be applied to man by two groups of investiga-
tors. and the estimated savings in the dtagno!>is 
of dij!;italts inltlxtc·ation alone are 5100 milhon. We 
have not been a hie to come up with a "savings" 
figure for rever~al for digitalis intoxication but it 
would obviously be much more. 
There are many other examples of dramatic cost 
saving, where baste research funding ha~:. been 
translated into eradication or prophylaxis of dis-
ease or new diagnostic or therapeutic methods. 
My analysis of tho»e places where we can get 
data shows that we are saving at least S<!5 billion 
a year. fu, you kno\\. the total budget of the NIH 
is about Sl.:l billion: approximately two-thirds of 
that is for research. Hence, we are getting at least 
a 20 to 1 dollar return. This fact cannot be over-
emphasized in terms of its importance to our so-
ciet) ·s unden.tandin~ ol the maJor implications 
of biomedical research eflorts. If even 90 percent 
of the mone.' is "wasted" in a fbcal sense. we are 
savmg 20 times the total expenditure a<; a mini-
mum esumate. 
The Administration apparent!~ is stronj!;ly con-
sidering diversion of funds from biomedical re-
sean·h to health -<·are delivery. Health-tare deliv-
ery is indeed necessary and should be upgraded, 
but the costs thereof should not be balanced 
against biomedical research [ :~9] and biomedical 
research training [40]. Instead. I submit that 
biomedical research should be balanced against 
other forms of Government-sponsored research. 
For example. what are the economic values of these 
other endeavors such as !>endin~ a man to the 
moon. or of huilding an SST? Most economists feel 
these are going to cost. rather than sa,·e. us money: 
the \oncorde built by the French is an example of 
erronet1us estimate" of the income to be derived 
from such work. 
It ts ot mterest that the Admtnistration ·, budget 
last year for the 'ational Institute of Allergy and 
lnfecuous Disea~es, the one insti tute for which I 
had the most mformation. called for a decrea<.e tn 
extramural funds of from 871 milliun to $67 million 
despite the vast amounts of money saved by 
research sponsored by this institute. Thb is not 
compatible with {'. A. Weinberger's statement 
that we must assign priorities and decrease funds 
to those a reas which are not payin~ off. Surely this 
is paying off. The abol ition of training grants will 
"save" only about S2.000.000 yearly. Further. the 
cuntract mechanism bemj!; used increasin~\y. at 
the :-.JCI especially. just won't support the kind nf 
research we need. One clinician at Memorial Ho:.-
pital has satd 7\txon's abolttion of trainin~ grants 
has eradtcated young people from goinj!; into can-
cer research rather than eradicated cancer. We 
mount a " conquest and at the same tune dect-
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mate the troops.11 Even in the cancer area the Ad-
ministration has deleted over the past three years 
$168 million originally promised to the Cancer ln-
stitute in the conquest of cancer bill. 
What can we do about all this? There are several 
things that can be done. First of all , when submit-
ting a paper to a journal I would urge you, if it has 
any relevance to new methods of eradication, 
diagnosis, or treatment of disease, to publish not 
only the scientific data but attempt to get an 
estimate of the number of people involved, their 
average age, the age of onset, the cost of hospitali -
zation. and loss of income costs, and point out not 
only the scientific importance of this but the 
econom ic importance. Secondly. I would urge that 
your Journal include a periodic review of advances 
in dermatology which will save this country money. 
Thirdly. I urge you to disseminate to your member-
ship such information so that when they talk to 
their colleagues they can cite it. Fourthly, f urge 
you and your colleagues to furnish such data to 
your local science writers. most all of whom are 
very cooperat ive. Some of the data T furnished 
to the science writer oft he San Francisco Chronicle 
who, over a period of time. puhlished four full-
length front page articles in that newspaper; l 
believe that the senior Senator from California was 
bombarded by letters from laymen as a result. fn 
any event , this Senator has consistently been the 
advocate of the highest NlH budgets. About a year 
ago we had a meeting of about a dozen immunolo-
gists with eight or ten newspaper science writers in 
Atlantic City with the emphasis on new develop-
ments and what this would mean in terms of 
dollars. As a result, articles were published in 
various papers, among them two front page articles 
in The New York Times. This as you know is read 
religiously h~· commuters from New .Jersey and, as 
a result (l am told) Senator Case of 1 ew ,Jersey 
received a flood of letters and a special hill was 
passed gi,·ing $12 million more specifically for 
immunology. As you gathered, the National Insti-
tute for Allergy and Infectious Diseases has about 
$22 mill ion a year for immunologic extramural 
research. This was a marked increase. Unfortu-
nately. the allocated funds were impounded by the 
~ \ lnempl!!yment amongst biologh,u. now appears to 
have t-xceeded the national emplovment rate. and a 
survey of biologtsts. conducted by the American lnst itute 
of Biological Scientists, ·would seem tn indkate an 
abruptly deteriorating position for biological science< 
because ol increased student enrollment and decreased 
academic opportunities in this area. According to Betty 
Vetter. Head of the :::icientific Manpower C'ummis~ion in 
Washington. G()vemment forecasts indicate a ne'' short -
age of physical ~cienttsts and engineers and an oversup-
ply Ill' life ~crentists (biologi:.~s at the doctoml le,·el 
already outnumbering phys icist!. by about seven tn nnel 
and litt le expan!>ion of biolnjzy departments in institu-
tions oJ higher edu(•ation lor contemplated enlargements 
becallse of a decrease in ;-\ IH Junding. !Holden( ': Sci -
ence I R I :8:1 I. l9'i:ll 
Administration. A bill was passed recently which 
originally the Administration had t hreatened to 
veto; it included, among other things, extension of 
regional medical programs. Although there was an 
original threat to veto, the President not only 
didn't veto it but actually gave it some words of 
fai nt praise. 
ll is essential to get recent advances into the 
hands of the public in terms of dollar savings. Over 
the last three years I have made about a dozen 
visits to Washington to talk to senators or their 
administrative assistants. For example, one con-
servative Republican Senator was opposed to med-
ical research until he saw the figures of S20 saved 
for each $1 spent. He stated it was •'fiscally 
irresponsible" not to increase funds in this area to 
keep pace with innation and population growth: he 
subsequently became a s trong advocate of higher 
NIH funds . There is one exam ple of what can be 
done. 
However. for the collection and-dissemination of 
these data one individual can no longer do t he job. 
I believe a nation-wide organization is needed for 
people to evaluate new advances and forward the 
i11formation to all concerned so that they can get it 
into their local newspapers, to their colleagues. to 
their Congressmen, and to concerned citizens [41). 
The basic science societies could join the clinical 
societies to set up an office in Washington man-
aged on a full-time basis; the estimated cost would 
be $80.000 a year ••. From the 10,000 biologic and 
clinical scientists in this country, if 20 percent of 
them "joined." $100.000 could be raised. At the 
American Association of Immunologists in 1972, 
a show of hands of how many people would be will-
ing to donate S5 a year on a voluntary basis showed 
95 percent approval. 
There i~ inertia amongst the elder statesmen in 
most societies; f'm not speaking of the SID where 
the representation differs and in which t he Society 
is financially solvent. In most societies which lack 
such assets. the elder statesmen have been very 
reluctant to permit, even on a voluntary basis. 
solicitation of funds from their membership. This 
can be done in a manner which does not endanger 
the tax exemption status of any Society. An office 
in Washington could hopefully ge t data from the 
NIH , could work with t he Federated Societies that 
have an office in Bethesda, and could accumulate 
and disseminate cost benefit fi!(ures. Hopefull y 
this would lead the public to feel that current 
policies regarding medical research are penny wise 
and pound foolish. If so, this would have considera-
ble impact on federal financial support. r can't see 
any way to have any impact except by such cost 
benefit analysis and I believe that some mecha-
nism must be evolved rapidly if our biomedical 
·' Stone ,J , Chairman F'ederatinn of Amrrtcan Sci-
entists, Washmgton. D.C .. personal communication. 
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research establishment is to be preserved in any 
viable form. 
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Appendix A 
In .January 1973. President Nixon proposed ~ub­
stantial alterations in the tlow of education funds 
to medical colleges in his budget message. As a 
result of the priorities he set. the following actions 
have been taken. 
l. Training grants, fellowships. and career de-
velopment awards will be eliminated. 
2. Research gran1s will be reduced in a ll areas 
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except cancer and heart disease, and in these 
areas more reliance will be placed upon con-
tracts and re~ea rch directed from the Na-
tional Institutes of Health. 
:t General research support grants are being 
severely reduced and will eventually be elimi· 
nated. General research support grants were 
instituted to ;,timulate new research ideas, to 
provide money for pilot projects that were 
con!>idered worthy of support at the local 
level, and to fo~ter an academic atmosphere 
in medical stho<>b that was conducive lO 
~ood researth. 
4. All construction funds for health science 
facilities have been eliminated. 
5. The Regional Medical Programs were to have 
been eliminated but, due to Congressional 
furor, have been rein~tated lor one more year. 
6. Allied health grants have been terminated. 
The impact of these budgetary cuts will com-
promise the capacity of colleges of medicine to 
continue their turrent activities. 
Because the pmhlem~ of the University of Cin-
cinnati College of Medicine a re typical, this college 
has been used as an example of the plight of all 
medical schools. Tbe College of M edicine has a 
total budget of approximately $17 million, of which 
$8.71 million was in Federal !>upport in the 1972 
tiscal year. The comparable figure for the 1973 
fiscal year is S8.27 million. For fiscal year 197-1, 
$6,920,000 is estimated, and for fiscal year 1975, 
$5,620,000. By fi scal year 1975 the est imated loss 
of money from federal sources for this medical 
college will be S3.09 million. This loss represents 
3.').5 percent of all Federal support and 17.8 per-
cent of the total budget. Translating these dollars 
into people. there will he a loss of approxtmately 
:30 full-time teachers, 100 support ing staff, and 
125 students. 
The above wa' paraphra~ed wath the permission of the 
author lrnm an article h\ Rllhert S. Daniels. M.D. and 
Richard \V. Vilter, M.D. entitled "President :\ixon's 
Budget P roposals and the Medical College;,, .. which 
appeared in the Annals of Internal Medicine, Volume 79. 
l\o. I. Jul~ l973. 
